Last Updated on October 9, 2024 by The Health Master
Drug recall
Novartis, a leading pharmaceutical company, has initiated a voluntary nationwide drug recall of a specific lot of its Sandimmune® Oral Solution in the United States.
This action has been taken due to the identification of crystal formation in some bottles, potentially leading to incorrect dosing.
It is crucial to note that only one lot of Sandimmune® is affected, and other formulations remain unaffected by this issue.
Details of the Drug recall
1. Affected Product:
- Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL
- Packaged in 50 mL bottles
2. Intended Usage:
- The product is primarily used for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants.
- It may also be utilized in the treatment of chronic rejection in patients who have previously been treated with other immunosuppressive agents.
Risk Assessment
The crystallization of cyclosporine in Sandimmune Oral Solution raises concerns about the uniform distribution of the drug in the product.
This non-uniformity may lead to either under-dosing or over-dosing, both of which can have serious implications:
- Under-dosing: This scenario may result in lower exposures, potentially decreasing the drug’s efficacy. Ultimately, this could lead to graft rejection and loss in transplant patients.
- Over-dosing: Prolonged over-exposure may manifest as cyclosporine toxicity in the long term.
It is important to highlight that, as of now, Novartis has not received any reports of adverse events associated with this Drug recall.
Lot Information
- Affected Lot Number: FX001691
- Expiration Date: 12/2025
- Distribution Commencement: April 2023
- Distribution Area: Nationwide to wholesalers across the US
Response and Actions
In light of the recall, Novartis is taking the following steps:
- Distributors are being promptly informed through recall notification letters.
- Arrangements are being made for the return of the recalled lot by distributors, retailers, and consumers.
- Health care providers who have prescribed this product are being notified to contact their patients.
- Consumers possessing bottles from the recalled lot are advised to get in touch with their health care provider.
FDA Oversight
This drug recall is being carried out in coordination with the U.S. Food and Drug Administration to ensure patient safety and wellbeing.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Drug recall: Digoxin Tablets recalled due to label mix-up
Drug recall: Glenmark recalls this High BP drug due to quality reasons
Drug recall: Alembic, Aurobindo recall these drugs for this reason
Drug recall: Lupin Pharma recalled these Birth Control Pills
Drug recall: Sun Pharma, Alembic recall these drugs due to this reason
Drug recall: Dronabinol Capsules, Ziprasidone HCL Capsules recalled due to this reason
USFDA issues Warning Letters to 8 Pharma Companies
Unlocking Opportunities for Pharma: Pharmexcil’s Mission in Seoul 2023
Boosting Growth: Pharmaceutical MSME Landscape in India
Breakthrough Pediatric HIV Treatment Receives Tentative USFDA Approval
DCC proposes crucial amendments for enhancing Drug Regulation
USFDA Approval granted for Generic Sevelamer Carbonate Oral Suspension
Drug alert: DCGI issues alerts on two Falsified Drugs
Nutraceuticals in India: A step towards empowering Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: